Lilly’s Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
Eli Lilly and Company announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic...